Rapport Therapeutics (RAPP) Total Current Liabilities (2023 - 2026)

Rapport Therapeutics (RAPP) has 4 years of Total Current Liabilities data on file, last reported at $17.9 million in Q1 2026.

• On a quarterly basis, Total Current Liabilities rose 90.74% year-over-year to $17.9 million in Q1 2026; TTM through Mar 2026 was $17.9 million, a 90.74% increase from a year earlier, with the FY2025 full-year figure at $19.0 million, up 117.28% from the prior year.
• Total Current Liabilities for Q1 2026 stood at $17.9 million, down from $19.0 million in the prior quarter.
• Over the last five years, Total Current Liabilities for RAPP reached as high as $19.0 million in Q4 2025 and fell as low as $7.1 million in Q3 2024.
• Historically, Total Current Liabilities has averaged $11.7 million across 4 years, with a median of $9.4 million in 2025.
• Across the five-year window, Total Current Liabilities fell 0.41% in 2024 and soared 117.28% in 2025, its largest moves.
• Year by year, Total Current Liabilities stood at $8.8 million in 2023, then dropped by 0.41% to $8.8 million in 2024, then surged by 117.28% to $19.0 million in 2025, then declined by 6.05% to $17.9 million in 2026.
• Per Business Quant data, the three most recent Total Current Liabilities figures were $17.9 million in Q1 2026, $19.0 million in Q4 2025, and $14.3 million in Q3 2025.